



Programme Track 2: Treatment & Patient Care

Monday, September 16

17.00 Opening Plenary

18.30 Welcome Reception

Tuesday, September 17

07.00 Breakfast Seminar

08.00 Plenary

09.30 Break

10.00 – 12.30 Parallel Sessions

Organised Session:

Viral Haemorrhagic Fevers: Advances in prevention, case management and diagnostics

Abstract Session:

539

Chemical water quality in inpatient therapeutic feeding centres: Potential risks to paediatric severe acute malnutrition patients and proposed management strategies

Ali S.I., Turnbull J., Arnold M., Holt F., Narang T., Falade S., Van Der Kam S., Fesselet J.F., Orbinski J. (Canada & The Netherlands)

574

metronidazole-sensitive organisms in children with SAM: An evaluation of the indication for empiric metronidazole treatment

Zangenberg M., Abdissa A., Johansen Ø.H., Tesfaw G., Girma T., Friis H., Kurtzhals J.A.L. (Denmark, Ethiopia & Norway)

553

Community Health Worker Led Art Delivery (CLAD) improved scheduled antiretroviral drug refill among men who have sex with men (MSM) in an identified HIV clinic, Lagos state, Nigeria

Ibiloye O., Osindero O., Oyekanmi F., Emerenini F., Omole T., Omoniyi D., Obioha E., Plang J., Akande P. (Nigeria)

558

HIV/AIDS-related knowledge and stigma among village health workers in rural Lesotho, Southern Africa: Analysis of data from get on research project

Lejone I.T., Lefu K., Kopo M., Kao M., Muhairwe J., Glass R.T., Labhardt D.N., Amstutz A. (Lesotho & Switzerland)



Programme Track 2: Treatment & Patient Care

12.30 Lunch break – Sponsored Session / Poster Tour

14.00 – 15.30 Parallel Sessions

Abstract Session:

522

30 years of dengue fatal dengue cases in Brazil

Nunes P.C.G., Sánchez-Arcila J.C., Nogueira R.M.R., Lima M.R.Q., dos Santos F.B.S. (Brazil)

978

The aetiology, neuroimaging and neurodevelopmental outcome of severe febrile encephalopathy in Malawian Children

Ray S., Fuller C., Stockdale E., Dwivedi R., Chetcuti K., Moxon C., Taylor T., Chimalizeni Y., Seydel K., Griffiths M.J. (UK & Malawi)

873

Viral respiratory infections are an important cause of non-malarial fever in a malaria hyperendemic region in burkina faso

Kabore B., Post A., Diallo S., Tinto H., Van der Ven A.J., de Mast Q. (The Netherlands & Burkina Faso)

728

Silent circulation of Zika virus in the state of Sergipe, northeast of Brazil

La Corte R., Jesus M. C. S., Batista M. V. A., Chagas R. D. O., Storti-de-Melo L. M. (Brazil)

1005

FIEBRE (Febrile Illness Evaluation in a Broad Range of Endemicities): A multi-site prospective observational study of causes of fever in Sub-Saharan Africa and southeast Asia

Hopkins H., Bassat Q., Chandler C.I.R., Crump J.A., Feasey N.A., Ferrand R.A., Laloo D.G., Mayxay M., Newton P.N., Mabey D.C.W. (UK, Spain, New Zealand Malawi, Zimbabwe & Laos)

15.30 Break

16.00 – 18.30 Parallel Sessions

Abstract Session:

155

Olorofim, an investigational orotomide antifungal agent with *in vitro* activity against *Madurella mycetomatis*

Lim W., Eadie K., Konings M., Fahal A.H., Birch M., Rijnders B., Verbon A., Van de Sande W.W.J. (The Netherlands, Sudan & UK)



Programme Track 2: Treatment & Patient Care

318

Field performance of the highly-sensitivity rapid diagnostic test in a setting of highly seasonal malaria transmission

Mwesigwa J., Slater H., Bradley J., Kandeh B., Saidy B., Ceesay F., Whitike C., Bouseman T., Van Geertruyden J.P., Drakeley C., Achan J., D'Alessandro U. (Gambia, Belgium, UK, USA & The Netherlands)

130

Role of platelet-rich plasma in healing diabetic and leprosy foot ulcers in resource poor setting

Joshi S.D (Nepal)

431

Disk diffusion and E-testing to determine the in vitro susceptibility of *M. mycetomatis* towards commonly used antifungal agents

Nyukonge B., Eadie K., Fahal A.H., Mouton J.W., Van de Sande W.W.J. (The Netherlands & Sudan)

296

School based clinical trials in low resource settings and factors associated with low intervention coverage: Lessons learned from the START-IPT trial

Khozoei B., Rehman A.M., Maiteki-Sebuguzi C., Gonahasa S., Kamya M.R., Staedke S.G. (UK & Uganda)

388

Field evaluation of automated digital malaria microscopy: EASYSCAN GO

Vongpromek R., Proux S., Ekawati L., Archasukan L., Bachman C., Bell D., Sutanto I., Dhorda M. (Thailand, Indonesia, USA & UK)

995

Liver health in HIV monoinfected and HIV/HBV coinfected individuals in Ghana

Villa G., Phillips R., Smith C., Owusu D., Abdullahi A., Sayeed L., Austin H., Chadwick D., Bhagani S., Geretti A.M. (UK & Ghana)

Organised Session:

High Tech in Low Resource Settings: exploring promising approaches for capacity building

Organised Session:

Konzo and cassava toxicity and the legacy of Hans Rosling in global health



Programme Track 2: Treatment & Patient Care

Wednesday, September 18

07.00 Breakfast Seminar

08.00 Plenary

09.30 Break

10.00 – 12.30 Parallel Sessions

Organised Session:
Schistosomiasis control through the ages

Abstract Session:

425

Diagnosis of genito-rectal schistosomiasis in a female traveller 8 years after exposure
Van Den Broucke S., Bottieau E. (Belgium)

345

The impact of mass drug administration in combination with indoor residual spraying on malaria burden in a high transmission setting in Uganda
Mulebeke R., Wanzira H., Van geertruyden J.P., Yeka A. (Belgium & Uganda)

404

Effectiveness of peer supervision in enhancing rational use of selected drugs among registered private drug shop operators in Busoga region, Uganda
Arthur B., Milton M., Stefan S.P., Phyllis A., Freddy E.K., Andreas M., David M., Henry W. (Uganda, Sweden & USA)

12.30 Lunch break – Sponsored Session / Poster Tour

14.00 Parallel Sessions

Abstract Session:

432

Uncovering the hidden: Surveillance of the emergence of anthelmintic resistance in human population with soil-transmitted helminths in southern Mozambique
Grau-Pujol B., Martinez-Valladares M., Gandasegui J., Cano J., Cossa A., Sacoor C., Muñoz J. (Spain, Mozambique, Argentina & UK)

514

A major hurdle in the elimination of urogenital schistosomiasis revealed: Identifying communities and health workers' perceptions and experiences of Female Genital Schistosomiasis in Ghana
Kukula V.A., MacPherson E.E., Tsey H.I., Stothard J.R., Theobald S., Gyapong M. (Ghana, Malawi & UK)



Programme Track 2: Treatment & Patient Care

672

Challenges in achieving elimination of lymphatic filariasis hotspots in Sierra Leone
Bah Y. M., Sonnie M., Conteh A., Paye J., Bah M. S., Sawyerr V., Veinoglou A., Hodges M., Koroma J. B., Zhang Y. (Sierra Leone, USA, Ghana & Senegal)

954

Cryptosporidium diarrhoea in adult patients at Queen Elizabeth Central Hospital, Blantyre, Malawi
Garg P., Smith C., Chirambo A., Matola B., Mallewa J., Hinton J., Gordon M.A. (Malawi & UK)

525

Antibiotic resistance pattern of urinary tract infections in a facility in Ethiopia: Experience of a clinician
Lomencho A. (Ethiopia)

15.30 Break

16.00 – 18.30 Parallel Sessions

Abstract Session:

545

Prolonged and persistent diarrhoea in children: A case-control study in Ethiopia
Zangenberg M., Johansen Ø.H., Abdissa A., Eshetu B., Kurtzhals J.A.L., Friis H., Sommerfelt H., Langeland N., Hanevik K. (Denmark, Norway & Ethiopia)

104

Epidemiological and clinical profile of immunosuppressed patients with imported strongyloidiasis: A substudy from a larger cohort of the +REDIVI Spanish collaborative network
Salvador F., Treviño B., Herrero-Martínez J.M., Rodríguez-Guardado A., Torrús D., Goikoetxea J., Zubero Z., Velasco M., Chamorro S., on behalf the REDIVI Collaborative Network. (Spain)

122

Testing novel diagnostic strategies to optimise public health interventions against human schistosomiasis: A study protocol of the freeBILy clinical trial in Madagascar
Fusco D., Rakotoarivelo R. A., Rakoto Andrianarivelo M., Puradiredja D. I., Klein P., Stahlberg K., Rakotozandrindrainy N., Rakotozandrindrainy R., Schwarz N.G., and the freeBILy consortium. (Germany & Madagascar)

580

Prevalence and intensity of schistosoma infection on Ijinga Island, Magu District, north-western Tanzania, after an intensified treatment protocol with praziquantel
Mueller A., Fuss A., Mazigo H.D. (Germany & Tanzania)

877

Seroprevalence study of anti-Ebolavirus (EBOV) immunoglobulin G (IgG) at the index site of 2013-2016 West African EBOV outbreak: Insight into early transmission and case fatality rate
Timothy J., Hall Y., Akoi-Boré J., Diallo B., Tipton T., Bower H., Glynn J., Carroll M. (UK, Guinea & Republic of Congo)



Programme Track 2: Treatment & Patient Care

980

Test and treat campaign: Adult individuals as a source of *Schistosoma mansoni* infection in fishing communities of Illemela and Nyamagana municipalities; north-western Tanzania

Bakuba E., Kaatano G., Kreibich S., Parisi S., Müller M., Kasang C., Mazigo H.D. (Tanzania & Germany)

996

Diagnostic accuracy of c-reactive protein and procalcitonin determination for the identification of bacterial infections in patients with persistent fever in the tropics

Van Duffel L., Jacobs J., Van Esbroeck M., Buyze J., Tsoumanis A., Yansouni C.P., Boelaert M., Verdonck K., Chappuis F., Bottieau E. (Belgium, Canada & Switzerland)

Organised Session:

Towards the ‘endgame’ for Neglected Tropical Diseases: the role of modelling to achieve control, transmission break, and elimination

Organised Session:

Advocacy networks addressing Neglected Tropical Diseases in Europe and beyond – an impressive recent approach of solidarity with the most neglected people worldwide

18.30 Conference Dinner

Thursday, September 19

07.00 Breakfast Seminar

08.00 Plenary

09.30 Break

10.00 – 12.30 Parallel Sessions

Organised Session:

Morbidity Management and Disability prevention for onchocerciasis

Abstract Session:

250

Onchocerciasis-associated epilepsy: The epidemiological evidence

Siewe Fodjo J.N., Menon S., Hotterbeekx A., Basanez M.G., Colebunders R. (Belgium & UK)

109

***Mycobacterium tuberculosis* genotypes causing pulmonary and extrapulmonary tuberculosis in southwest Ethiopia**

Tadesse M., Abebe G., de Rijk P., Meehan C., de Jong B.C., Rigouts L. (Ethiopia & Belgium)

498

Antibiotic prescription and its adequacy in four MSF projects in Africa

Koscalova A., Eibs T., Jimenez C., Lasry, E., Kohler G., Owen N.B., Turashvili M. (Austria, Spain, Slovakia & UK)



Programme Track 2: Treatment & Patient Care

12.30 Lunch break – Sponsored Session / Poster Tour

14.00 – 15.30 Parallel Sessions

Abstract Session:

576

A critical evaluation of the appetite test for children with severe acute malnutrition

Zangenbergh M., Abdissa A., Johansen Ø.H., Tesfaw G., Friis H., Briend A., Kurtzhals J.A.L., Girma T. (Denmark, Ethiopia, Norway & Finland)

928

Endemic leptospirosis in Sri Lanka: Value of clinical presentation, laboratory data and suspected case definition for early diagnosis

Nisansala G.G.T., Bandara A.W.M.K., Weerasekera M.M., Gunasekara T.D.C.P., Gamage C.D., Marasinghe M.G.C.P., Fernando S.S.N., Ranasinghe K.N.P. (Sri Lanka)

836

Mass campaign on non-communicable diseases - city of Kigali 2017: Assessing utility and effectiveness

Mukantagara M., Zinnen V., Kangabire M.T., Mbarushimana A., Tihon V., Ndayisaba G., Condo J. (Rwanda)

690

Characteristics of patients at risk of, or with newly diagnosed diabetes in a sub-urban township, South Africa: Smart2d baseline survey results

Delobelle P.A., Onagbiye S.O., De Man J., Manuga T., Hassen M., Puoane T. (South Africa & Belgium)

912

Emergence of diminished ciprofloxacin-susceptibility *Salmonella typhi* in an ongoing outbreak from Harare, Zimbabwe

Olaru I.D., Feasey N., Ferrand R., Mabey D., Hopkins H., Zinyowera S., Amos B., Tarupiwa A., Mashe T., Kranzer K. (Zimbabwe, UK & Malawi)

15.30 Break

16.00 – 18.30 Parallel Sessions

Abstract Session:

172

Noma prevalence study, northwest Nigeria 2018

Farley E., Modupe O.J., Schuurmans J., Saleh F., Ihekweazu C., Lenglet A., on behalf of the noma prevalence working group. (Nigeria, South Africa & The Netherlands)



Programme Track 2: Treatment & Patient Care

489

The drivers of antibiotic prescription and use in three MSF projects in Africa

Koscalova A., Eibs T., Jimenez C., Lasry E., Grohma P., Kohler G., Bakhit R. (Austria, Spain & Slovakia)

854

Estimation of incidence risk of mortality and serious adverse events for antileishmanial therapies: An infectious diseases data observatory systematic review of published literature from 1980 to 2018

Singh S., Dahal P., Ngu R., Maguire B., Olliari P.L., Stepniewska K., Guérin P.J. (UK)

717

Telementoring with project ECHO, A pilot project in Myanmar

Tun N.N., Noe T.M., Lee C., Lee A., Hilmers D.C., Wilkins E., Smithuis F.M. (Myanmar & Australia)

808

Cost-effectiveness of different strategies of strongyloides stercoralis screening and treatment among migrants from endemic countries to the European Union

Wikman-Jorgensen P., Shedrawy J., Llenas-García J., Gascon J., Bisoffi Z., Muñoz J., Requena-Méndez A. (Spain, Sweden & Italy)

919

TMek: A quantitative rapid diagnostic test for malaria

Giacometti M., Milesi F., Coppadoro P.L., Ferrari G., Fiore G.B., Rizzo A., Grande R., Gismondo M.R., Corbellino M., Antinori S., Bertacco R. (Italy)

Organised Session:

Cutaneous Leishmaniasis: Global burden, mental consequences and treatment opportunities

Friday, September 20

08.00 – 10.00 Parallel Sessions

08.00 Abstract Session:

424

Oral fexinidazole for Gambiense human African Trypanosomiasis: The WHO treatment guidelines

Franco J.R., Priotto G., Barrett M., Chappuis F., Diarra A., Ebeja A.K., Kazumba L., Lejon V., Lindner A., Mwamba Miaka E., Olema E., Seixas J., Simarro P.P., WHO guidelines development group for human African trypanosomiasis (HAT) treatment (Switzerland)



Programme Track 2: Treatment & Patient Care

163

The challenge of the laboratory diagnosis in a confirmed congenital Zika virus syndrome in utero: A case report

Soriano-Arandes A., Sulleiro E., Rodó C., Frick M.A., Rando A., Suy A., Espiau M., Martín-Nalda A., Pumarola T., Soler-Palacín P. (Spain)

336

Imported malaria in western Romania: A 9 year retrospective study

Lupu M.A., Lazureanu V.E., Pasat A.A., Olariu T.R. (Romania)

375

Community-based screening for chagas disease and strongyloidiasis among Latin American migrants in Alicante, Spain

Ramos-Rincón J.M., Llenas-García J., Gil-Anguita C., Gregori-Colomé J., Garijo-Saiz A.M., Wikman-Jorgensen P., Torrús-Tendero D., Ventero-Martín M.P., Flores-Chávez M., Navarro-Beltrá M., on behalf of the #AlicanteSinChagas Network (Spain)

926

Chagas disease in the United Kingdom: A review of cases managed at the hospital for tropical diseases, London 1995 – 2018

Nolder D., Dawood N., Garcia Mingo A., Gonzalez Sanz M., De Sario V., Alvarez M., Lowe P., Yacoub S., Moore D., Chiodini P.L. (UK & Spain)

08.00 Abstract Session:

Addressing the social determinants and consequences of tuberculosis

Dixit K., Wingfield T. (Nepal & UK)

About 125 patients one year after trichiasis surgery in Mali

Touré A. (Mali)

CNS infections in Africa: Epidemiology, diagnostics, and treatment in 2019

Mosepele M. (Botswana)

08.00 Abstract Session – Late Breakers:

1147

The EKOS project - Development of a novel concept to ensure infectiological-medical care in German tertiary care hospitals of patients suffering from high consequence infectious diseases

Stitterich N., Heim K., Grünewald T., Rößler S., Schöpke T., Koeppen M., Lichtner E., Rösler U., Gröschke D., Kratz T. (Germany)

1152

Mortality among confirmed Lassa Fever cases during the 2017–2019 outbreak in Ondo State, Nigeria

Ilesanmi O., Ayodeji O., Abejegah C. (Nigeria)



Programme Track 2: Treatment & Patient Care

1165

Elder abuse in a selected medical officer of health area in the district of Colombo: Prevalence and correlates of physical, emotional, financial abuse and neglect from first community based study in Sri Lanka

Samaraweera P.C., Sivayogan S., Kathriarachchi S. (Colombo & Sri Lanka)

1167

Drug discovery efforts and development of kinetoplastid assays Novartis institutes for tropical diseases

Pei A., Saldivia Concepcion M., Cheung H., Chen Y.L., Rao S., Williams S., Gable J., Song J.G., Patra D., Jiricek J. (USA)

08.30 Organised Session:

Mycetoma: An update on new evidence, approaches and tools for managing one of the most neglected NTDs

08.30 Organised Session:

Optimizing case management for severe malaria in the most remote endemic settings: The CARAMAL Multi-country initiative

08.30 Organised Session:

Footwear and Footcare in NTDs / NCD – it is part of treatment not the cosmetic or luxury

10.00 Break

10.30 Organised Session:

Neglected Tropical Diseases (NTDs) in Europe: Emerging diseases on the move

10.30 Organised Session:

Skin NTDs

10.30 Organised Session:

Practical steps in addressing disability and wellbeing in NTD research and programmes

12.00 **Closing Plenary**